Intuitive Surgical, Inc. $ISRG is Rockport Wealth LLC’s 6th Largest Position

Rockport Wealth LLC reduced its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 3.8% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 54,873 shares of the medical equipment provider’s stock after selling 2,187 shares during the period. Intuitive Surgical makes up about 4.6% of Rockport Wealth LLC’s investment portfolio, making the stock its 6th biggest holding. Rockport Wealth LLC’s holdings in Intuitive Surgical were worth $25,292,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently added to or reduced their stakes in the company. Draper Asset Management LLC boosted its holdings in Intuitive Surgical by 41.9% in the 4th quarter. Draper Asset Management LLC now owns 5,029 shares of the medical equipment provider’s stock worth $2,848,000 after acquiring an additional 1,485 shares during the period. Deutsche Bank AG raised its stake in shares of Intuitive Surgical by 9.6% during the fourth quarter. Deutsche Bank AG now owns 1,522,191 shares of the medical equipment provider’s stock valued at $862,108,000 after purchasing an additional 132,966 shares during the period. Oppenheimer Asset Management Inc. raised its stake in shares of Intuitive Surgical by 29.3% during the fourth quarter. Oppenheimer Asset Management Inc. now owns 71,077 shares of the medical equipment provider’s stock valued at $40,255,000 after purchasing an additional 16,119 shares during the period. Procyon Advisors LLC lifted its position in shares of Intuitive Surgical by 787.8% during the fourth quarter. Procyon Advisors LLC now owns 4,794 shares of the medical equipment provider’s stock worth $2,715,000 after purchasing an additional 4,254 shares in the last quarter. Finally, Robinhood Asset Management LLC purchased a new position in shares of Intuitive Surgical in the fourth quarter valued at $6,478,000. 83.64% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

ISRG has been the subject of a number of recent analyst reports. JPMorgan Chase & Co. lowered their price target on shares of Intuitive Surgical from $625.00 to $550.00 and set an “overweight” rating for the company in a report on Wednesday, April 22nd. Leerink Partners cut their price objective on shares of Intuitive Surgical from $622.00 to $573.00 and set an “outperform” rating on the stock in a report on Wednesday, April 22nd. The Goldman Sachs Group set a $558.00 target price on Intuitive Surgical in a research note on Wednesday, May 27th. Zacks Research lowered Intuitive Surgical from a “strong-buy” rating to a “hold” rating in a research report on Monday, March 30th. Finally, Deutsche Bank Aktiengesellschaft cut their price target on Intuitive Surgical from $440.00 to $366.00 and set a “sell” rating on the stock in a research note on Tuesday, June 2nd. One analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Intuitive Surgical currently has a consensus rating of “Moderate Buy” and a consensus price target of $565.31.

Insider Buying and Selling at Intuitive Surgical

In related news, EVP Gary Loeb sold 400 shares of the company’s stock in a transaction that occurred on Wednesday, June 10th. The stock was sold at an average price of $424.14, for a total transaction of $169,656.00. Following the sale, the executive vice president directly owned 5,720 shares of the company’s stock, valued at approximately $2,426,080.80. This represents a 6.54% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Amy L. Ladd sold 119 shares of Intuitive Surgical stock in a transaction on Wednesday, April 29th. The stock was sold at an average price of $463.50, for a total transaction of $55,156.50. Following the completion of the transaction, the director directly owned 120 shares of the company’s stock, valued at approximately $55,620. This represents a 49.79% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 7,169 shares of company stock worth $3,059,135 over the last quarter. 0.60% of the stock is owned by corporate insiders.

Intuitive Surgical News Summary

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: BMO Capital initiated coverage with an Outperform rating, adding to the case that Intuitive Surgical can continue to defend its leadership in robotic surgery. BMO Capital Starts Intuitive Surgical (ISRG) at Outperform
• Positive Sentiment: Several articles note that ISRG heads into earnings with strong procedure momentum, da Vinci 5 adoption, and a history of beating estimates, which supports hopes for another solid quarter. Intuitive Surgical Pre-Q2 Analysis: Buy, Hold or Sell the Stock Now?
• Positive Sentiment: Intuitive Surgical’s Ion lung biopsy study is approaching a data readout, highlighting a potential new growth avenue beyond core robotic surgery. Intuitive Surgical’s Ion Lung Biopsy Study Nears Data Readout, Eyeing New Growth in Diagnostics
• Neutral Sentiment: Commentary around Intuitive Surgical’s leadership versus rising global competition is mixed: the company is using AI features and a broad ecosystem to defend share, but competition remains a watch item. Can ISRG Defend Its Leadership as Global Competition Intensifies?
• Neutral Sentiment: Some coverage frames the move as a pre-earnings repositioning event, with investors weighing recent analyst target cuts, margin pressure from tariffs, and broader medical-device weakness more than any new company-specific setback. Intuitive Surgical Falls as Target Cut and Pre-Earnings Jitters Weigh on Shares

Intuitive Surgical Price Performance

ISRG opened at $388.97 on Thursday. Intuitive Surgical, Inc. has a 12-month low of $378.50 and a 12-month high of $603.88. The stock has a market capitalization of $137.76 billion, a PE ratio of 47.15, a P/E/G ratio of 3.09 and a beta of 1.46. The firm’s fifty day moving average price is $418.39 and its 200 day moving average price is $469.98.

Intuitive Surgical (NASDAQ:ISRG) last released its earnings results on Tuesday, April 21st. The medical equipment provider reported $2.50 earnings per share for the quarter, topping the consensus estimate of $2.08 by $0.42. The company had revenue of $2.77 billion during the quarter, compared to the consensus estimate of $2.62 billion. Intuitive Surgical had a net margin of 28.15% and a return on equity of 15.98%. The company’s revenue was up 23.0% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.81 EPS. On average, equities research analysts forecast that Intuitive Surgical, Inc. will post 8.57 earnings per share for the current fiscal year.

Intuitive Surgical Profile

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.